Senti Biosciences, Inc. Annual Report: A Performance Summary

I’ve put together this guide to help you understand how Senti Biosciences performed this year. Use this as a "cheat sheet" to decide if this company fits your investment goals.

1. What does this company do?

Senti Biosciences is a biotech company developing "gene circuit" technology. Think of their platform as a way to program cells with "if-then" instructions. These cells can sense their environment and only activate their treatment when they detect specific cancer markers. This precision aims to solve a major problem in current cancer therapies: accidentally destroying healthy cells.

2. Financial performance: The "Investment Phase"

For the year ending December 31, 2025, Senti reported a loss of $78.4 million, an improvement from the $85.2 million loss in 2024. The company spent $58.1 million on research and development to move their SENTI-202 treatment through clinical trials. Revenue remains very low at $0.3 million, coming mostly from older research partnerships. Senti currently spends more than it earns, relying on outside funding to keep the lights on.

3. Major wins: The SENTI-202 Progress

The big news is the progress of SENTI-202, a treatment for relapsed or hard-to-treat Acute Myeloid Leukemia (AML).

• Promising Data: In early trials, 50% of patients responded to the treatment. Notably, 42% achieved complete remission, with most showing no detectable cancer at a molecular level. This is a vital benchmark for longer survival in AML patients.
• Regulatory Boost: The FDA granted "Orphan Drug Designation," which provides seven years of market exclusivity and tax credits. They also granted "RMAT" status, which gives Senti closer FDA guidance and a faster path toward potential approval.

4. Financial health: The "Cash Runway"

As of December 31, 2025, Senti held $38.2 million in cash. With the company spending about $65 million a year to operate, their cash supply is limited. To raise money, Senti has issued more shares to the public. For you as an investor, this means your percentage of ownership in the company is reduced as more shares are created.

5. Key risks

• Cash Burn: Senti does not have enough cash to fund operations for the next 12 months without raising more money. If they cannot raise capital on good terms, they may have to issue more shares or cut back on research.
• Clinical Success: The company’s value depends almost entirely on SENTI-202. If future trials fail or reveal safety issues, the company’s main asset could lose its value.
• Regulatory Hurdles: RMAT status doesn't guarantee success. The FDA may still require large, expensive trials that take years to complete.
• Partnership Dependency: Senti relies on partners like BlueRock Therapeutics. If these partners end their deals, Senti loses both a key source of income and a vote of confidence in their technology.

6. Future outlook

The goal is simple: keep clinical trials moving while managing cash. Watch for updates on SENTI-202 as it moves into larger testing phases. Management is looking for funding that doesn't require issuing more shares, such as government grants or new partnerships. Success in 2026 depends on extending their cash runway while keeping their clinical results strong.

Investor Takeaway: Senti is a high-risk, high-reward play. The technology shows real promise in early trials, but the company is currently in a race against time to secure more funding before their cash runs out. If you are considering an investment, keep a close eye on their next quarterly update regarding their cash position and any new partnership announcements.